Prelude Therapeutics to Attend Citizens JMP Life Sciences Conference

WILMINGTON, Del., May 09, 2024 – Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a company engaged in precision oncology at the clinical stage, has announced its participation in the upcoming Citizens JMP Life Sciences Conference. This event is scheduled to be held in New York City on May 13 and 14. On Tuesday, May 14, at 1:00 p.m. ET, Kris Vaddi, Ph.D., the Chief Executive Officer, along with Jane Huang, M.D., the President and Chief Medical Officer of Prelude, will engage in a fireside chat. This discussion will be available for live viewing via webcast through the company’s website under the Events and Presentations section. The recording of this session will be archived and accessible on the company's website for a period of 90 days.

Prelude Therapeutics is dedicated to the development of innovative drug candidates that target critical pathways in cancer cells. Their diverse pipeline consists of proprietary small molecule compounds that are highly differentiated and potentially best-in-class, aimed at addressing clinically validated pathways for cancers in specific underserved patient populations. Currently, the company's clinical development pipeline includes three candidates: PRT3789, a potent and selective SMARCA2 degrader administered intravenously; PRT2527, a potent and selective CDK9 inhibitor; and PRT3645, a next-generation CDK4/6 inhibitor.

In addition to these molecules, Prelude is advancing PRT7732, a potent, highly selective, orally bioavailable SMARCA2 degrader. The company is also collaborating with AbCellera to discover, develop, and commercialize up to five next-generation antibody drug conjugate (ADC) products. This partnership combines AbCellera’s expertise in antibody discovery and development with Prelude’s capabilities in medicinal chemistry and drug development.